1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Non Hodgkin Lymphoma (NHL)
  • 1.2.3 Follicular Lymphoma
  • 1.2.4 Solid Tumors
  • 1.2.5 Breast Cancer
  • 1.2.6 Ovarian Cancer
  • 1.2.7 Osteosarcoma
  • 1.2.8 Neuroblastoma
  • 1.2.9 Prostate Cancer
• 1.3 Market by Application
  • 1.3.1 Global Radioimmunotherapy Market Share by Application: 2020 VS 2026
  • 1.3.2 Tumor Antigens
  • 1.3.3 Radionuclides
  • 1.3.4 Antibodies
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Radioimmunotherapy Market Perspective (2015-2026)
• 2.2 Global Radioimmunotherapy Growth Trends by Regions
  • 2.2.1 Radioimmunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Radioimmunotherapy Historic Market Share by Regions (2015-2020)
  • 2.2.3 Radioimmunotherapy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Radioimmunotherapy Players by Market Size
  • 3.1.1 Global Top Radioimmunotherapy Players by Revenue (2015-2020)
  • 3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2015-2020)
• 3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Radioimmunotherapy Revenue
• 3.4 Global Radioimmunotherapy Market Concentration Ratio
  • 3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2019
• 3.5 Key Players Radioimmunotherapy Area Served
• 3.6 Key Players Radioimmunotherapy Product Solution and Service
• 3.7 Date of Enter into Radioimmunotherapy Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Radioimmunotherapy Breakdown Data by Type (2015-2026)

• 4.1 Global Radioimmunotherapy Historic Market Size by Type (2015-2020)
• 4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2021-2026)

5 Radioimmunotherapy Breakdown Data by Application (2015-2026)

• 5.1 Global Radioimmunotherapy Historic Market Size by Application (2015-2020)
• 5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Radioimmunotherapy Market Size (2015-2026)
• 6.2 North America Radioimmunotherapy Market Size by Type (2015-2020)
• 6.3 North America Radioimmunotherapy Market Size by Application (2015-2020)
• 6.4 North America Radioimmunotherapy Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Radioimmunotherapy Market Size (2015-2026)
• 7.2 Europe Radioimmunotherapy Market Size by Type (2015-2020)
• 7.3 Europe Radioimmunotherapy Market Size by Application (2015-2020)
• 7.4 Europe Radioimmunotherapy Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Radioimmunotherapy Market Size (2015-2026)
• 8.2 China Radioimmunotherapy Market Size by Type (2015-2020)
• 8.3 China Radioimmunotherapy Market Size by Application (2015-2020)
• 8.4 China Radioimmunotherapy Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Radioimmunotherapy Market Size (2015-2026)
• 9.2 Japan Radioimmunotherapy Market Size by Type (2015-2020)
• 9.3 Japan Radioimmunotherapy Market Size by Application (2015-2020)
• 9.4 Japan Radioimmunotherapy Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Radioimmunotherapy Market Size (2015-2026)
• 10.2 Southeast Asia Radioimmunotherapy Market Size by Type (2015-2020)
• 10.3 Southeast Asia Radioimmunotherapy Market Size by Application (2015-2020)
• 10.4 Southeast Asia Radioimmunotherapy Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Bayer Healthcare Pharmaceuticals
  • 11.1.1 Bayer Healthcare Pharmaceuticals Company Details
  • 11.1.2 Bayer Healthcare Pharmaceuticals Business Overview
  • 11.1.3 Bayer Healthcare Pharmaceuticals Radioimmunotherapy Introduction
  • 11.1.4 Bayer Healthcare Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020))
  • 11.1.5 Bayer Healthcare Pharmaceuticals Recent Development
• 11.2 BioSynthema
  • 11.2.1 BioSynthema Company Details
  • 11.2.2 BioSynthema Business Overview
  • 11.2.3 BioSynthema Radioimmunotherapy Introduction
  • 11.2.4 BioSynthema Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.2.5 BioSynthema Recent Development
• 11.3 Clarity Pharmaceuticals
  • 11.3.1 Clarity Pharmaceuticals Company Details
  • 11.3.2 Clarity Pharmaceuticals Business Overview
  • 11.3.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
  • 11.3.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.3.5 Clarity Pharmaceuticals Recent Development
• 11.4 Curasight
  • 11.4.1 Curasight Company Details
  • 11.4.2 Curasight Business Overview
  • 11.4.3 Curasight Radioimmunotherapy Introduction
  • 11.4.4 Curasight Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.4.5 Curasight Recent Development
• 11.5 Endocyte
  • 11.5.1 Endocyte Company Details
  • 11.5.2 Endocyte Business Overview
  • 11.5.3 Endocyte Radioimmunotherapy Introduction
  • 11.5.4 Endocyte Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.5.5 Endocyte Recent Development
• 11.6 Immunomedics
  • 11.6.1 Immunomedics Company Details
  • 11.6.2 Immunomedics Business Overview
  • 11.6.3 Immunomedics Radioimmunotherapy Introduction
  • 11.6.4 Immunomedics Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.6.5 Immunomedics Recent Development
• 11.7 Molecular Insight Pharmaceuticals
  • 11.7.1 Molecular Insight Pharmaceuticals Company Details
  • 11.7.2 Molecular Insight Pharmaceuticals Business Overview
  • 11.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Introduction
  • 11.7.4 Molecular Insight Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.7.5 Molecular Insight Pharmaceuticals Recent Development
• 11.8 Nordic Nanovector
  • 11.8.1 Nordic Nanovector Company Details
  • 11.8.2 Nordic Nanovector Business Overview
  • 11.8.3 Nordic Nanovector Radioimmunotherapy Introduction
  • 11.8.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.8.5 Nordic Nanovector Recent Development
• 11.9 PDL Biopharma
  • 11.9.1 PDL Biopharma Company Details
  • 11.9.2 PDL Biopharma Business Overview
  • 11.9.3 PDL Biopharma Radioimmunotherapy Introduction
  • 11.9.4 PDL Biopharma Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.9.5 PDL Biopharma Recent Development
• 11.10 Philogen
  • 11.10.1 Philogen Company Details
  • 11.10.2 Philogen Business Overview
  • 11.10.3 Philogen Radioimmunotherapy Introduction
  • 11.10.4 Philogen Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.10.5 Philogen Recent Development
• 11.11 RadioMedix
  • 10.11.1 RadioMedix Company Details
  • 10.11.2 RadioMedix Business Overview
  • 10.11.3 RadioMedix Radioimmunotherapy Introduction
  • 10.11.4 RadioMedix Revenue in Radioimmunotherapy Business (2015-2020)
  • 10.11.5 RadioMedix Recent Development
• 11.12 Stella Pharma
  • 10.12.1 Stella Pharma Company Details
  • 10.12.2 Stella Pharma Business Overview
  • 10.12.3 Stella Pharma Radioimmunotherapy Introduction
  • 10.12.4 Stella Pharma Revenue in Radioimmunotherapy Business (2015-2020)
  • 10.12.5 Stella Pharma Recent Development
• 11.13 Telix Pharmaceuticals
  • 10.13.1 Telix Pharmaceuticals Company Details
  • 10.13.2 Telix Pharmaceuticals Business Overview
  • 10.13.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
  • 10.13.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020)
  • 10.13.5 Telix Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer

Global Radioimmunotherapy Scope and Market Size
Radioimmunotherapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Radioimmunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
Solid Tumors
Breast Cancer
Ovarian Cancer
Osteosarcoma
Neuroblastoma
Prostate Cancer

Market segment by Application, split into
Tumor Antigens
Radionuclides
Antibodies

Based on regional and country-level analysis, the Radioimmunotherapy market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Radioimmunotherapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Bayer Healthcare Pharmaceuticals
BioSynthema
Clarity Pharmaceuticals
Curasight
Endocyte
Immunomedics
Molecular Insight Pharmaceuticals
Nordic Nanovector
PDL Biopharma
Philogen
RadioMedix
Stella Pharma
Telix Pharmaceuticals